HomeAI · summaries
Storia in 7 fonti
Insilico Medicine's rentosertib shows potential to slow aging in landmark Phase III trial
Insilico Medicine's AI-discovered drug rentosertib enters Phase III trials for lung fibrosis, targeting cellular senescence with implications for
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
cryptobriefing.com
Insilico Medicine's rentosertib shows potential to slow aging in landmark Phase III trial
Insilico Medicine's AI-discovered drug rentosertib enters Phase III trials for lung fibrosis, targeting cellular senescence with implications for
- ·
thenextweb.com
Insilico says its AI-designed lung drug lowered biological age markers in a 42-patient trial
Six proteomic ageing clocks agreed patients on Insilico’s AI-designed lung drug looked younger. The authors cannot yet rule out the treated lung.
